Bli medlem
Bli medlem

Du är här


Xvivo Perfusion: XVIVO has completed a private placement of shares

The board of directors of Xvivo Perfusion AB (publ) ("Xvivo" or the
"Company") (NASDAQ OMX First North: XVIVO) has, pursuant to an
authorization from the annual general meeting held on April 29, 2014,
resolved to issue 1,950,000 new shares in Xvivo through a private
placement directed to a group of qualified Swedish and international
investors (the "Private Placement"). The Private Placement was
announced on June 25, 2014 and was fully subscribed.

The subscription price for each new share was set to SEK 37.50 through
a book-building procedure. Through the Private Placement Xvivo raises
SEK 73,125,000 before issue costs. Compared to the past 10 days'
volume weighted average price (10 day VWAP) for Xvivo's share, the
price of the shares issued in the Private Placement meant a discount
of 2.6 per cent. Compared to the closing price on 25 June 2014, the
corresponding discount was 5.1 per cent. The Company decided to
increase the size of the Private Placement from the announced SEK 50
million to approximately SEK 73 million given the strong interest
among investors.

The newly issued shares carry the right to dividend on the first
record date for dividend following the registration of the shares
with Euroclear Sweden AB.

The reason for deviating from the shareholders' preferential rights by
conducting a directed new share issue is that the board of directors
believes that it is beneficial for the Company and its shareholders
to seize this opportunity to raise additional capital on attractive
terms, thus facilitating a faster built up of the Company's working
capital for the U.S. and European launch of the XPS and STEEN
Solution as well as investment into new indications. The board of
directors believes that the proceeds generated in the Private
Placement will benefit all current shareholders of the Company.

"XVIVO Perfusion expects to receive market approval for STEEN Solution
and XVIVO Perfusion System (XPS) in the US market in the next few
months. Furthermore, XPS has recently been approved for the European
market (CE marking). As there is great interest in these innovative
products, the capital contribution greatly strengthens the company's
ability to satisfy the market demand by building up its working
capital more rapidly. Furthermore, XVIVO Perfusion will be able to
more rapidly take advantage of the potential that exists in the
development of new indications for warm perfusion using Steen
Solution", says Magnus Nilsson, CEO of XVIVO Perfusion.

Through the Private Placement, the number of shares and votes in Xvivo
will be increased with 1,950,000 from 19,562,769 to 21,512,769. The
share capital will increase by approximately SEK 49,840 to
approximately SEK 549,840. The shares issued in the Private Placement
correspond to approximately 9.1 per cent of the share capital and
votes in Xvivo following the Private Placement. Payment of the shares
issued in the Private Placement shall occur no later than 1 July
2014. The Board of Directors of Xvivo retains the right to extend the
payment period at its discretion.

Pareto Securities AB ("Pareto Securities") acted as sole bookrunner
and lead manager in connection with the Private Placement.


The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, New Zeeland, Hong Kong, Japan, Canada, Singapore,
Switzerland or South Africa. The distribution of this press release
in certain other jurisdictions may be restricted. The information in
this press release shall not constitute an offer to sell or the
solicitation of an offer to purchase any securities in Xvivo in any
jurisdiction. This press release does not constitute, or form part
of, an offer or solicitation to purchase or subscribe for securities
in the United States. The securities referred to herein may not be
offered or sold in the United States absent registration or an
exemption from registration as provided in the U.S. Securities Act of
1933, as amended. Xvivo does not intend to register any portion of
the offering of the securities in the United States or to conduct a
public offering of the securities in the United States. Copies of
this announcement are not being distributed or sent and may not be
distributed or sent to the United States, Australia, New Zeeland,
Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa.

Xvivo has not resolved to offer to the public shares or rights in any
Member State of the European Economic Area and no prospectus or other
offer documentation has been prepared or will be prepared in
connection with the Private Placement. Within such Member States of
the European Economic Area which has implemented the Prospectus
Directive (each, a "Relevant Member State"), no action has been
undertaken as of this date to make an offer to the public of shares
or rights requiring a publication of a prospectus in any Relevant
Member State. As a result hereof, the shares or rights may only be
offered in Relevant Member States: (a) to a qualified investor (as
defined in the Prospectus Directive or under applicable law. For the
purposes hereof, the expression an "offer to the public of shares or
rights" in any Relevant Member State means the communication, in any
form, of sufficient information on the terms of the offer and the
shares or rights to be offered so as to enable an investor to decide
to purchase any securities, as the same may be varied in a Relevant
Member State due to the implementation of the Prospectus Directive in
that Member State and the expression "Prospectus Directive" means
Directive 2003/71/EC including any relevant implementing measure in
each Relevant Member State.

Pareto Securities AB is acting for Xvivo and no one else in connection
with the Private Placement and will not be responsible to anyone
other than Xvivo for providing the protections afforded to its
clients or for providing advice in relation to the Private Placement
and/or any other matter referred to in this announcement.

Pareto Securities AB accepts no responsibility whatsoever and makes no
representation or warranty, express or implied, for the contents of
this announcement, including its accuracy, completeness or
verification or for any other statement made or purported to be made
by Pareto Securities AB, or on its behalf, in connection with Xvivo
and the New Shares or the Private Placement, and nothing in this
announcement is, or shall be relied upon as, a promise or
representation in this respect, whether as to the past or future.
Pareto Securities AB accordingly disclaims to the fullest extent
permitted by law all responsibility and liability whether relating to
damages, contract or otherwise which it might otherwise have in
respect of this announcement or any such statement.

Any investors in the Private Placement will further be deemed to
acknowledge (i) the information in this press release, (ii) that the
investors are not relying (for purposes of making any investment
decision or otherwise) upon any advice, counsel or representations
(whether written or oral) of Xvivo, Pareto Securities or any of their
respective affiliates, and (iii) that they have consulted with their
own legal, regulatory, tax, business, investment, financial, and
accounting advisers to the extent they have deemed necessary, and
they have made their own investment decisions based upon their own
judgment and upon any advice from such advisers as they have deemed
necessary. The company has not given, and the investors have not
received from the company, any non-public information in connection
with the Private Placement.

Forward-looking statements

This press release contains forward-looking statements that reflect
management's current views with respect to future events and
potential financial performance. Although Xvivo believes that the
expectations reflected in such statements are reasonable, no
assurance can be given that such expectations will prove to have been
correct. Accordingly, results can differ materially from those set
out in the forward-looking statements as a result of various factors.

For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,

For further information on XVIVO Perfusion's business, please refer to
the company's website,

The information was submitted for publication on June 26, 2014 at 8:30

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ OMX First North and
has the ticker symbol XVIVO. More information can be found on the
website The Certified Adviser is Redeye,


XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.